Humira

European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Will new biosimilars hurt blockbuster autoimmune drug?
Will new biosimilars hurt blockbuster autoimmune drug?New biosimilars may harm the sales of this autoimmune blockbuster.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Express Scripts’ 2016 Drug Trend Report: 7 things to knowReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.
10 highlights from AAO 2016
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
FDA approves biosimilar to HumiraFDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching